Use of t2c001 in peripheral diseasesAnwendung von t2c001 bei peripheren Gefäßerkrankungen
    t2cure’s cell therapy is available through cooperating clinical centres
    t2cure cooperates with experienced partners in research and in the industry.
    t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
    t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.

    Use of t2c001 in peripheral diseases

    Posted below are scientific articles about t2c001 in peripheral artery diseases and about the indication thromboangiitis obliterans: 

    Walter DH, Krankenberg H, Balzer JO, Kalka C, Baumgartner I, Schlüter M, Tonn T, Seeger F, Dimmeler S, Lindhoff-Last E, Zeiher AM: Intraarterial Administration of Bone Marrow Mononuclear Cells in Patients With Critical Limb Ischemia. A Randomized-Start, Placebo-Controlled Pilot Trial (PROVASA). Circ Cardiovasc Interv. 2011. 4(1): 26-37.

    Fadini GP, Agostini C, Avogaro A: Autologous stem cell therapy for peripheral arterial disease. Meta-analysis and systematic review of literature. Atherosclerosis. 2010 Mar;209(1):10-7

    Arkkila P: Thromboangiitis obliterans (Buerger's disease). Orphanet J Rare Dis. 2006 Apr 27;1:14.

    Olin JW: Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol. 2006 Jan;18(1):18-24.